Selection, engineering, and in vivo testing of a human leukocyte antigen–independent T-cell receptor recognizing human mesothelin
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0301175 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Martyn J Hiscox und 17 weiteren Autor:innen. Beteiligte Einrichtung: Research, Adaptimmune, Abingdon, Oxfordshire, United Kingdom. Hauptthemen laut MEDLINE: Mesothelin, Neoplasms. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Adaptimmune.
Abstract (Originalsprache)
Background
Canonical α/β T-cell receptors (TCRs) bind to human leukocyte antigen (HLA) displaying antigenic peptides to elicit T cell−mediated cytotoxicity. TCR-engineered T-cell immunotherapies targeting cancer-specific peptide-HLA complexes (pHLA) are generating exciting clinical responses, but owing to HLA restriction they are only able to target a subset of antigen-positive patients. More recently, evidence has been published indicating that naturally occurring α/β TCRs can target cell surface proteins other than pHLA, which would address the challenges of HLA restriction. In this proof-of-concept study, we sought to identify and engineer so-called HLA-independent TCRs (HiTs) against the tumor-associated antigen mesothelin.
Methods
Using phage display, we identified a HiT that bound well to mesothelin, which when expressed in primary T cells, caused activation and cytotoxicity. We subsequently engineered this HiT to modulate the T-cell response to varying levels of mesothelin on the cell surface.
Results
The isolated HiT shows cytotoxic activity and demonstrates killing of both mesothelin-expressing cell lines and patient-derived xenograft models. Additionally, we demonstrated that HiT-transduced T cells do not require CD4 or CD8 co-receptors and, unlike a TCR fusion construct, are not inhibited by soluble mesothelin. Finally, we showed that HiT-transduced T cells are highly efficacious in vivo, completely eradicating xenografted human solid tumors.
Conclusion
HiTs can be isolated from fully human TCR–displaying phage libraries against cell surface-expressed antigens. HiTs are able to fully activate primary T cells both in vivo and in vitro. HiTs may enable the efficacy seen with pHLA-targeting TCRs in solid tumors to be translated to cell surface antigens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research, Adaptimmune, Abingdon, Oxfordshire, United Kingdom.
ORCID-Profile: Martyn J Hiscox, Victoria Elizabeth Anderson
Förderung
- Adaptimmune
Zitieren
APA
Hiscox, M. J., Wasmuth, A., Williams, C. L., Foot, J. N., Wiedermann, G. E., Fadda, V., Boiani, S., Cornforth, T. V., Wikiert, K. A., Bruton, S., Cartwright, N., Anderson, V. E., Barnes, C. S., Vieira, J. V., Birch-Machin, I., Gerry, A. B., Miller, K., & Pumphrey, N. J. (2024). Selection, engineering, and in vivo testing of a human leukocyte antigen–independent T-cell receptor recognizing human mesothelin. PLOS ONE. https://doi.org/10.1371/journal.pone.0301175
Vancouver
Hiscox MJ, Wasmuth A, Williams CL, Foot JN, Wiedermann GE, Fadda V, et al. Selection, engineering, and in vivo testing of a human leukocyte antigen–independent T-cell receptor recognizing human mesothelin. PLOS ONE. 2024. doi:10.1371/journal.pone.0301175
BibTeX
@article{Hiscox2024,
author = {Hiscox, Martyn J and Wasmuth, Alexandra and Williams, Chris L and Foot, Jaelle N and Wiedermann, Guy E and Fadda, Valeria and Boiani, Sara and Cornforth, Terri V and Wikiert, Karolina A and Bruton, Shaun and Cartwright, Neil and Anderson, Victoria Elizabeth and Barnes, Christopher S and Vieira, Joao V and Birch-Machin, Ian and Gerry, Andrew B and Miller, Karen and Pumphrey, Nicholas J},
title = {Selection, engineering, and in vivo testing of a human leukocyte antigen–independent T-cell receptor recognizing human mesothelin},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0301175}
}
EUVIMED